 AUSTIN, Texas, May 20, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced initial results from the CIRCULATE-Japan trial, the largest prospective molecular residual disease MRD-guided study to date. Part of CIRCULATE-Japan, the prospective, observational GALAXY study uses Nateras personalized and tumor-informed circulating tumor DNA ctDNA test, SignateraTM, to monitor MRD status in patients with stage II-IV or relapsed colorectal cancer CRC who are amenable to radical surgical resection. 